T-cell receptor recognizing peptide-major histocompatibility complex on antigen-presenting cells (TCR-pMHC complex)

The T-cell receptor recognizing peptide-major histocompatibility complex on antigen-presenting cells refers to the molecular interaction by which a T-cell receptor (TCR), a membrane-bound immunoglobulin superfamily receptor, engages and specifically binds a short peptide displayed by a major histocompatibility complex (MHC) molecule on the surface of antigen-presenting cells. This recognition event is essential for adaptive immune response initiation: it triggers intracellular signaling cascades via associated CD3 molecules, leading to T cell activation, proliferation, and effector functions (such as cytotoxicity or helper activities). TCR recognition is highly specific, governed by complementary structures (CDR loops) binding to both the peptide and MHC helices, and forms the molecular basis of self/non-self discrimination; failure of this discrimination is implicated in autoimmune disease, while modulation can enable cancer immunotherapy. Therapeutic approaches include engineering TCRs for adoptive T cell therapy, modulation with small molecule drugs, and use of TCR-mimic antibodies, but managing off-target and autoimmune effects remains a significant safety concern[1][3][6][5].

Other names

T-cell receptor (TCR) interacting with peptide-MHC (pMHC)TCR-pMHC complexTCR-APC interactionTCR-antigen complexαβ TCR recognizing peptide-MHC

Antigen-specific engagement (Therapeutic agents mimic, block, or enhance TCR recognition of peptide-MHC[6].); Activation/inhibition of TCR signaling (via downstream effectors such as CD3, ZAP-70, ITAMs[3].); Redirecting T cell specificity (engineered TCRs or TCR-mimic antibodies[6].); Immunosuppression (drugs disrupting TCR signaling like calcineurin inhibitors[5].)